Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Active not recruiting 5Terminated 3Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 132Other solid neoplasm 12CNS 11Gastrointestinal 6Tumor-Agnostic 4Head & Neck 3Gynecologic 3Sarcoma 2Genitourinary 2Breast 2Other 1Dermatologic 1

Conditions

Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 65Nivolumab 59Ipilimumab 33Cyclophosphamide 23Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13fludarabine 13cemiplimab 13Opdualag 12Blood Specimen Collection 11binimetinib 10aldesleukin 9Radiosurgery 9Interleukin-2 9encorafenib 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Aminolevulinic Acid 6Radiotherapy 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pemetrexed × Dermatologic × Clear all
NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Recruiting
214 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡